Menumenu
  • Home
  • Women's health and paediatrics Publications

Women's health and paediatrics Publications

Women's health and paediatrics Publications

  • Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study.Abstract

    BACKGROUND: The expiration of patents of brand inhalation medications and the ongoing pressure on healthcare budgets resulted in a growing market for generics. AIM: To study the use of brand and generic inhalation medication and the frequency of swtching between brand and generic and between devices

    Engelkes M, van Blijder veen JC, Overbeek JA, Kuiper J, Herings RCM, Sturkenboom Mcjm, deJongste JC, Verhamme KMC, Janssens HM. J Asthma. 2018 Nov 29; 55 1086-1094.
  • Increased risk of morbidities and health-care utilisation in children born following preterm labour compared with full-term labour: A population-based study.Abstract

    AIM: Recent evidence is emerging indicating long-term effects in infants born after an episode of preterm labour (PTL), even if birth is at term. This population-based study compared long-term rates of outcomes and health-care utilisation (HCU) inhildren born following spontaneous preterm labour, irrespective of gestational age at delivery or of an uncomplicated pregnancy (SPTLu), with children born following full-term labour (FTL), overall stratified by comorbidity status and assessed using a composite morbidity measure (CM)

    Houben E, Smits E, Pimenta JM, Black LK, Bezemer ID, Penning-van Beest FJ. J Paediatr Child Health. 2018 Oct 4; 55 446-453.
  • Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study.Abstract

    BACKGROUND: Despite the concerns about a potential increased risk of skin cancer and lymphoma with the use of topical tacrolimus and pimecrolimus, no population-based studies have given an overview of the use of these drugs in Europe. OBJECTIVE: Toassess the use of topical tacrolimus and pimecrolimus in children and adults in Europe

    Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegard A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Drugs Real World Outcomes. 2018 May 7; 5 109-116.
  • A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study).Abstract

    Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children. Objective: The aim of this study was toompare incidence rates (IRs) of lymphoma and skin cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects

    Castellsague J, Kuiper JG, Pottegard A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Clin Epidemiol. 2018 10 299-310.
  • Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.Abstract

    OBJECTIVE: Acid suppression with histamine-2 receptor antagonists (H2RAs) or proton pump inhibitors (PPIs) is recommended for children with persistent gastroesophageal reflux disease symptoms. In this retrospective, observational postauthorizationtudy, we aimed to assess and compare safety outcomes in pediatric first-time users of esomeprazole, other PPIs or H2RAs

    Houben E, Johansson S, Nagy P, Penning-van Beest FJA, Kuipers EJ, Herings RMC. Curr Med Res Opin. 2017 Nov 24; 34 577-583.
  • Thrombotic risk minimization for Diane-35 and generics.Abstract

    BACKGROUND: This study aimed to evaluate the effect of risk minimization measures on cyproterone acetate/ethinylestradiol (CPA/EE) use in the Netherlands. Potential indications of use and concomitant pharmacy dispensing of other hormonal contraceptves (HC) were assessed among new users in 2011, 2012, and 2014

    Bezemer ID, Smits E, Penning-van Beest FJA, Asiimwe A, Herings RMC. Pharmacoepidemiol Drug Saf. 2017 Sep 26; 26 1411-1417.
  • Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.Abstract

    OBJECTIVE: To describe the characteristics of pediatric patients prescribed proton pump inhibitors (PPIs) vs those of pediatric patients prescribed histamine-2-receptor antagonists (H2RAs). METHODS: Observational studies were conducted using The Helth Improvement Network (THIN) and the PHARMO Database Network

    Ruigomez A, Kool-Houweling LMA, Garcia Rodriguez LA, Penning-van Beest FJA, Herings RMC. Curr Med Res Opin. 2017 Jun 09; 33 2251-2259.
  • Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study.Abstract

    BACKGROUND: Several studies showed a bidirectional association between type 2 diabetes and psychiatric disorders in adults. Because there is limited information on the association between type 1 diabetes (T1D) and psychiatric disorders (including pychiatric medication use) in children and adolescents, we assessed frequency of use of these medications before and after the onset of T1D

    FazeliFarsani S, Abdullah-Koolmees H, Souverein PC, de Boer A, Mantel-Teeuwisse AK. Pediatr Diabetes. 2017 Apr 24; 121 - 128.
  • Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes.Abstract

    OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 1years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System

    Ahmadizar F, Souverein PC, Arets HG, deBoer A, Maitland-van der Zee AH. Pediatr Pulmonol. 2016 Nov; 51 (11): 1113-1121.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study.Abstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 (6): 433-40.